JP2010505869A5 - - Google Patents

Download PDF

Info

Publication number
JP2010505869A5
JP2010505869A5 JP2009531568A JP2009531568A JP2010505869A5 JP 2010505869 A5 JP2010505869 A5 JP 2010505869A5 JP 2009531568 A JP2009531568 A JP 2009531568A JP 2009531568 A JP2009531568 A JP 2009531568A JP 2010505869 A5 JP2010505869 A5 JP 2010505869A5
Authority
JP
Japan
Prior art keywords
composition
group
disease
treating
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2009531568A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010505869A (ja
JP5362572B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2007/080231 external-priority patent/WO2008042921A2/en
Publication of JP2010505869A publication Critical patent/JP2010505869A/ja
Publication of JP2010505869A5 publication Critical patent/JP2010505869A5/ja
Application granted granted Critical
Publication of JP5362572B2 publication Critical patent/JP5362572B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2009531568A 2006-10-02 2007-10-02 テトラ−o−置換ブタン架橋修飾ndga誘導体、それらの合成および薬学的使用 Expired - Fee Related JP5362572B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US82778306P 2006-10-02 2006-10-02
US60/827,783 2006-10-02
PCT/US2007/080231 WO2008042921A2 (en) 2006-10-02 2007-10-02 Tetra-o-substituted butane-bridge modified ndga derivatives, their synthesis and pharmaceutical use

Publications (3)

Publication Number Publication Date
JP2010505869A JP2010505869A (ja) 2010-02-25
JP2010505869A5 true JP2010505869A5 (https=) 2011-11-17
JP5362572B2 JP5362572B2 (ja) 2013-12-11

Family

ID=39269174

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2009531568A Expired - Fee Related JP5362572B2 (ja) 2006-10-02 2007-10-02 テトラ−o−置換ブタン架橋修飾ndga誘導体、それらの合成および薬学的使用

Country Status (6)

Country Link
US (4) US8232277B2 (https=)
EP (1) EP2076125B1 (https=)
JP (1) JP5362572B2 (https=)
CN (1) CN101547602B (https=)
ES (1) ES2449237T3 (https=)
WO (1) WO2008042921A2 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010011117A2 (ko) * 2008-07-25 2010-01-28 국립암센터 Ndga를 포함하는 트란스글루타미나제 억제용 조성물
US20100093872A1 (en) * 2008-10-15 2010-04-15 Erimos Pharmaceuticals Llc Stable aqueous formulations of water insoluble or poorly soluble drugs
EP2699236B1 (en) 2011-04-22 2018-06-20 Napo Pharmaceuticals Inc Pharmacologically optimized multimodal drug delivery system for nordihydroguiaretic acid (ndga)
WO2012166778A2 (en) * 2011-05-31 2012-12-06 The Johns Hopkins University Conjugates of nitroimidazoles and their use as chemotherapeutic agents
JP6255038B2 (ja) * 2013-02-26 2017-12-27 トリアクト セラピューティクス,インク. 癌治療
CN105764501A (zh) 2013-07-26 2016-07-13 现代化制药公司 改善比生群治疗效益的组合物
JP7504304B2 (ja) 2021-01-19 2024-06-21 エリモス・ファーマシューティカルズ・リミテッド・ライアビリティ・カンパニー コロナウイルス抗ウイルス剤としてのテラメプロコールおよびノルジヒドログアイアレチン酸(ndga)誘導体

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4708964A (en) * 1984-02-09 1987-11-24 Chemex Pharmaceuticals Lipoxygenase inhibitors
EP0290442A4 (en) * 1986-11-19 1990-07-03 Chemex Pharmaceuticals Inc MEDICINAL PREPARATIONS AND MIXTURES THEREOF, ORGANIC COMPOSITIONS AND METAL SALTS.
WO1988003800A1 (en) * 1986-11-19 1988-06-02 Chemex Pharmaceuticals, Inc. Lipoxygenase inhibitors
US6579880B2 (en) * 2000-06-06 2003-06-17 Ortho-Mcneil Pharmaceutical, Inc. Isoxazoles and oxadiazoles as anti-inflammatory inhibitors of IL-8
WO2003103583A2 (en) * 2002-06-10 2003-12-18 Oklahoma Medical Research Foundation A method for using tethered bis(polyhydroxyphenyls) and o-alkyl derivatives thereof in treating inflammatory conditions of the central nervous system
CA2595606C (en) * 2005-01-27 2014-12-16 Erimos Pharmaceuticals Llc Oral formulations for delivery of catecholic butanes including ndga compounds
US7741357B1 (en) * 2006-04-17 2010-06-22 Johns Hopkins University Heterocyclic and carbonate derivatives of NDGA and their use as new anti-HIV and anti-cancer agents

Similar Documents

Publication Publication Date Title
JP2010505865A5 (https=)
JP2010505869A5 (https=)
JP2012525393A5 (https=)
JP2021063088A5 (https=)
JP2020507589A5 (https=)
JP2008543854A5 (https=)
JP2018518537A5 (https=)
JP2004516314A5 (https=)
JP2017537940A5 (https=)
JP2015511638A5 (https=)
JP2016534063A5 (https=)
JP2016512202A5 (https=)
JP2006506425A5 (https=)
RU2013121788A (ru) Ингибиторы репликации вич
JP2009502743A5 (https=)
JP2013512277A5 (https=)
JP2015537020A5 (https=)
JP2016510769A5 (https=)
RU2012118974A (ru) Комбинации ингибитора pi3k и ингибитора мек
JP2017523225A5 (https=)
JP2016531126A5 (https=)
JP2014530838A5 (https=)
RU2007101653A (ru) Производные 1-азабицикло[3.3.1]нонанов
JP2015521156A5 (https=)
RU2011124894A (ru) Триазолотиадиазоловый ингибитор протеинкиназы с-мет